Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound: A Clinical Comparison
Dr. RP, MD — Board-Certified, Emergency Medicine & Critical Care Medicine — Founder, Analog Precision Medicine
During COVID — the most intense period of my clinical career — I watched metabolic disease kill people in real time. The patients who deteriorated fastest in the ICU were overwhelmingly those carrying visceral obesity, insulin resistance, and metabolic dysfunction that had been silently building for decades. When patients ask me about GLP-1 agonists, I bring that perspective. These are serious pharmacological interventions in a disease that kills more people than most cancers.
Same Class, Different Drugs
Semaglutide is in both Ozempic (type 2 diabetes approval, up to 2.0 mg weekly) and Wegovy (weight management approval, 2.4 mg weekly). Same molecule, different doses and regulatory indications. Tirzepatide is in Mounjaro (diabetes) and Zepbound (weight management) — a dual GIP/GLP-1 agonist activating two incretin pathways instead of one.[1,2]
The Numbers
Tirzepatide consistently outperforms semaglutide for weight loss: 20.9% body weight reduction in SURMOUNT-1 versus 15–17% across the STEP trials.[2,3] For a 250-pound patient, that's roughly 52 vs. 38 pounds. For type 2 diabetes, tirzepatide also shows greater A1c reductions, with more patients reaching non-diabetic levels.[4]
For cardiovascular outcomes, semaglutide leads. The SELECT trial showed a 20% reduction in major cardiovascular events in overweight and obese adults with established CV disease.[5] Tirzepatide's cardiovascular outcomes trial is still ongoing.
Side Effects That Matter
GI symptoms (nausea, vomiting, diarrhea) are dose-related and usually transient with slow titration. Tirzepatide may be modestly better tolerated. Beyond the headlines: gallstone risk increases with rapid weight loss, pancreatitis risk is rare but real, and both carry thyroid C-cell tumor warnings contraindicating use in patients with medullary thyroid carcinoma or MEN2 family history.
“Without resistance training and adequate protein, patients may lose 25–40% of total weight as lean tissue. In an aging population, that's accelerated sarcopenia.”
The side effect that warrants the most attention: muscle loss. Without resistance training and adequate protein, patients may lose 25–40% of total weight as lean tissue.[6] In an aging population, that's accelerated sarcopenia — a serious trade-off that doesn't make headlines the way weight loss does.
Which One?
Type 2 diabetes with moderate weight goals: semaglutide (Ozempic) has the deepest evidence base.
Maximum weight loss: tirzepatide (Zepbound/Mounjaro).
Established cardiovascular disease: semaglutide (Wegovy) based on SELECT trial data.
GI sensitivity: tirzepatide may be better tolerated.
Regardless of choice: resistance training, protein intake of 1.0–1.2 g/kg/day, regular metabolic monitoring, and a plan for medication discontinuation are non-negotiable parts of responsible prescribing.
References
- 1.FDA Prescribing Information: Semaglutide (Ozempic/Wegovy).
- 2.Jastreboff AM, et al. Tirzepatide for obesity. N Engl J Med. 2022;387:205–216. (SURMOUNT-1)
- 3.Wilding JPH, et al. Semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. (STEP 1)
- 4.Frias JP, et al. Tirzepatide vs semaglutide in type 2 diabetes. N Engl J Med. 2021;385:503–515. (SURPASS-2)
- 5.Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity. N Engl J Med. 2023;389:2221–2232. (SELECT)
- 6.Heymsfield SB, et al. Mechanisms and management of obesity. N Engl J Med. 2017;376:254–266.
Dr. RP, MD is dual board-certified in Emergency Medicine and Critical Care Medicine and is the founder of Analog Precision Medicine, a precision medicine practice in Southern California. This article is for educational purposes only and does not constitute medical advice or establish a physician-patient relationship.
← Back to Blog